CTLA4 and hypophysitis: It is worth noting that the risk of hypophysitis was higher among patients receiving anti‐PD1/PDL1 (incidence 6.3%) and lower among those subjects on anti‐CTLA4 (incidence 5.0%) monotherapy, compared to the data reported in the current literature.